BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 29136244)

  • 21. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
    Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
    Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells.
    Sunayama J; Sato A; Matsuda K; Tachibana K; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
    Neuro Oncol; 2010 Dec; 12(12):1205-19. PubMed ID: 20861085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nitidine chloride inhibits the malignant behavior of human glioblastoma cells by targeting the PI3K/AKT/mTOR signaling pathway.
    Liu M; Wang J; Qi Q; Huang B; Chen A; Li X; Wang J
    Oncol Rep; 2016 Oct; 36(4):2160-8. PubMed ID: 27498786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
    Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
    Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
    Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
    Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergistic antitumor effect of BRMS1 and sorafenib via inhibition of the PI3K/AKT/mTOR/ERK signaling pathway.
    Jin J; Guo Y; Liu Y; Wang Z; Yang X; Sun S
    Oncol Rep; 2019 Sep; 42(3):1183-1193. PubMed ID: 31233204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of mTOR in glioblastoma.
    Duzgun Z; Eroglu Z; Biray Avci C
    Gene; 2016 Jan; 575(2 Pt 1):187-90. PubMed ID: 26341051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapamycin-mediated mTOR inhibition attenuates survivin and sensitizes glioblastoma cells to radiation therapy.
    Anandharaj A; Cinghu S; Park WY
    Acta Biochim Biophys Sin (Shanghai); 2011 Apr; 43(4):292-300. PubMed ID: 21367753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth inhibitory effect of rapamycin in Hodgkin-lymphoma cell lines characterized by constitutive NOTCH1 activation.
    Nagy N; Hajdu M; Márk Á; Király PA; Tóth M; Dankó T; Csóka M; Sebestyén A
    Tumour Biol; 2016 Oct; 37(10):13695-13704. PubMed ID: 27473087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SYK regulates mTOR signaling in AML.
    Carnevale J; Ross L; Puissant A; Banerji V; Stone RM; DeAngelo DJ; Ross KN; Stegmaier K
    Leukemia; 2013 Nov; 27(11):2118-28. PubMed ID: 23535559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
    Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC
    Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
    Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
    BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
    Martelli AM; Evangelisti C; Chiarini F; McCubrey JA
    Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 17β‑Estradiol protects against interleukin‑1β‑induced apoptosis in rat nucleus pulposus cells via the mTOR/caspase‑3 pathway.
    Guo HT; Yang SD; Zhang F; Liu S; Yang DL; Ma L; Wang H; Ding WY
    Mol Med Rep; 2019 Aug; 20(2):1523-1530. PubMed ID: 31257459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Wild‑type IDH1 affects cell migration by modulating the PI3K/AKT/mTOR pathway in primary glioblastoma cells.
    Shen X; Wu S; Zhang J; Li M; Xu F; Wang A; Lei Y; Zhu G
    Mol Med Rep; 2020 Sep; 22(3):1949-1957. PubMed ID: 32705169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation.
    Roca H; Varsos Z; Pienta KJ
    J Biol Chem; 2008 Sep; 283(36):25057-73. PubMed ID: 18611860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
    Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
    J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.